Yahoo
NasdaqCM - Delayed Quote USD

eXoZymes, Inc. (EXOZ)

4.1300 +0.1200 (+2.99%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for EXOZ
  • Previous Close 4.0100
  • Open 4.1800
  • Bid 6.1000 x 100
  • Ask 7.6000 x 100
  • Day's Range 4.0100 - 4.1900
  • 52 Week Range 3.2400 - 18.4000
  • Volume 6,008
  • Avg. Volume 8,514
  • Market Cap (intraday) 38.428M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.1900
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Zacks Rating Neutral

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

www.exozymes.com

32

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

EXOZ
62.11%
S&P 500 (^GSPC)
10.73%

1-Year Return

EXOZ
67.34%
S&P 500 (^GSPC)
11.11%

3-Year Return

EXOZ
62.79%
S&P 500 (^GSPC)
81.91%

5-Year Return

EXOZ
62.79%
S&P 500 (^GSPC)
64.59%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -74.74%

  • Return on Equity (ttm)

    -187.16%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -10.19M

  • Diluted EPS (ttm)

    -1.1900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.65M

  • Total Debt/Equity (mrq)

    29.69%

  • Levered Free Cash Flow (ttm)

    -3.25M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: